Depression Clinical Trial
Official title:
An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators
Major depression is increasingly recognized to be a chronic and highly recurrent condition,
which results in significantly increased health problems. One possible mechanism that may
contribute to treatment resistance is increased production and release of chemicals called
proinflammatory cytokines in patients with major depression. These chemicals mediate the
body's response to infectious agents like bacteria and have been shown to be increased by
psychological stress. They produce the symptoms that we associate with being sick, including
fever, malaise and changes in sleep and appetite. Several lines of evidence indicate that
proinflammatory cytokines may contribute to the development of major depression and may thus
represent a novel target for the pharmacological treatment of the disorder.
The TNF-alpha antagonist, Infliximab (Remicade®), is an infusion style drug approved by the
FDA for the treatment of inflammatory conditions like Crohns disease and rheumatoid
arthritis. The researchers are conducting a study to see if the infliximab (Remicade®) is
more effective than placebo in acutely reducing symptoms of depression in patients who have
elevated proinflammatory markers and have not responded to, or been unable to tolerate, at
least two previous treatments in the current depressive episode. Proinflammatory markers are
measured by a simple blood test for C-Reactive Protein (CRP) levels in the body.
After appropriate screening to determine eligibility, 64 subjects with treatment resistant
depression will be randomized to receive three infusions of either infliximab (Remicade®) or
placebo (salt water) in the Emory Infliximab Infusion Center in the Division of Digestive
Diseases, Emory University School of Medicine. Subjects will be followed for 12 weeks with
evaluations at weeks 0 (baseline), 1, 2, 3, 4, 6, 8, 10 and 12. The first infliximab
(Remicade®) infusion will occur at the first (Baseline) visit. The second infusion will occur
at Study Week 2 (the third visit). The third infusion will occur at Study Week 6 (Visit 6).
The choice of three infusions, and the infusion schedule, is based on current recommendations
for the use of infliximab (Remicade®) in conditions for which it has received FDA approval.
Subjects will be evaluated for twelve weeks by trained clinicians for changes in depression
symptoms and improvements in quality of life. In addition, a physician will evaluate subjects
each visit to make sure they are remaining healthy. Blood will be drawn at baseline prior to
infusion and all subsequent visits to check labs for safety but also to evaluate potential
relationships between changes in inflammatory activity and therapeutic response. After Study
Week 12, participants will be monitored by phone, every 4 weeks during the 22-Week Post Study
Follow-up Phase to assess physical and psychiatric symptoms in the period following the final
infusion. At the baseline and Week 8 visits, subjects will be admitted to the Atlanta
Clinical Translational Science Institute (ACTSI), a research unit in the Emory Hospital, for
an extended evaluation. The purpose of coming to the ACTSI will be for researchers to
evaluate whether treatment with infliximab improves endocrine function, inflammation, sleep
and thinking abilities in people who are depressed. For all other visits (Week 1, 2, 4, 6, 10
and 12), participants will come for an office visit in the Winship Cancer Institute.
Major depression has become a health crisis of epidemic proportions in the modern world. The
prevalence of major depression has risen over the last several generations in every country
examined, and age of symptom onset has decreased. Currently the fourth leading health burden
worldwide, major depression will rank second after cardiac disease as a cause of
international medical morbidity by the year 2020. One in six individuals in the United States
will experience an episode of major depression in his or her lifetime, and the risk of
subsequent episodes rises dramatically once a person has been depressed. Indeed, depression
is now recognized to be a highly chronic and recurrent illness. On average, patients with
major depression are symptomatic 60% of the time, even when receiving community-standard
antidepressant treatment. Recent estimates place the economic burden of depression in the
United States at 83 billion dollars a year.
Depression is associated with greater disability than are most other chronic illnesses and is
a risk factor for mortality. Suicide ranks among the top ten causes of death in the United
States, and best estimates suggest that 60-70% of people who kill themselves are clinically
depressed. Between 10-15% of severely depressed people eventually commit suicide. In
addition, many studies indicate that depression significantly increases all-cause mortality
independently of suicide. Depression predicts the later development of a number of medical
conditions, including cardiac and cerebrovascular disease, hypertension,diabetes,obesity and
the metabolic syndrome,dementia, and cancer. Depression also markedly increases mortality in
patients who are medically ill and has been associated with decreased responses to
pharmacological treatments for cancer and hepatitis C.
Unfortunately, most patients with depression do not experience a complete resolution of
symptoms with antidepressant treatment and 10-20% of patients are refractory to all currently
available modalities, including electroconvulsive shock (ECT) therapy. ECT is often effective
in patients who have failed adequate trials of multiple antidepressants, but is associated
with the risk of anesthesia and with significant short term memory impairment. Responses to
ECT are short-lived, and many patients who respond subsequently relapse, even when on
maintenance antidepressants. In addition to efficacy issues, many patients are unable to
tolerate side effects associated with antidepressants or ECT. The risks of not responding to
(or tolerating) treatment have been highlighted by recent studies documenting that
partial—but incomplete—response is associated with an increased risk of full symptomatic
relapse (even when on therapy) and a worse long term disease course, as well as with
significantly impaired quality of life. Treatment resistance also results in a six times
increase in direct health care costs. These factors highlight the tremendous need to identify
novel treatment strategies, especially for depressed patients who are unresponsive to
conventional therapies.
One possible mechanism that may contribute to treatment resistance is increased
proinflammatory cytokine production and release. Several lines of evidence indicate that
proinflammatory cytokines participate in the pathophysiology of major depression and may thus
represent a novel target for the pharmacological treatment of the disorder. First, a high
percentage of patients who receive cytokine therapies (such as interferon-alpha for malignant
melanoma or hepatitis C infection) develop depressive symptoms, and many patients meet full
criteria for major depression. Interferon-alpha-induced depressive symptoms can be
ameliorated by pre-treatment with an antidepressant and respond to antidepressants once they
have emerged. Second, many studies report that, as a group, medically healthy patients with
depression exhibit elevated measures of proinflammatory cytokines, including tumor necrosis
factor (TNF)-alpha, interleukin (IL)-1 and IL-6. Moreover, a positive relationship between
serum concentrations of proinflammatory cytokines and severity of depressive symptoms has
been recently reported. Third, antidepressants have been shown to have anti-inflammatory
activity and may work—at least in part—by reducing inflammatory activity, given evidence that
clinical response is associated with reductions in cytokine levels. These data raise the
possibility that cytokine antagonists, such as the chimeric anti-TNF-alpha antibody
infliximab, might have antidepressant efficacy. Of special relevance to this proposal,
patients who are treatment resistant have been shown to exhibit increased inflammatory
activity (as reflected by increased plasma concentrations of interleukin [IL]-6 and the
soluble IL-6 receptor [sIL-6R]), suggesting that cytokine antagonists might be especially
effective in these patients.
Providing care to patients with inflammatory bowel disease has given us the clear clinical
impression that infliximab rapidly improves mood and energy levels in many patients prior to
any demonstrable changes in bowel pathology. This impression is in line with a growing body
of evidence suggesting that TNF-alpha antagonists improve emotional functioning and fatigue
in patients receiving these agents for rheumatoid arthritis and inflammatory bowel disease.
These findings in patients with inflammatory diseases are consistent with the notion that
TNF-alpha antagonists such as infliximab might provide acute symptomatic relief for medically
healthy patients with treatment-resistant major depression and that symptom improvement might
result from decreased inflammatory activity. Moreover, medically healthy depressed patients
with increased inflammatory activity may be most likely to benefit from anti-TNF-alpha
therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |